ImmunoPrecise Antibodies (IPA) Short-Term Debt to Capital

Corporate company logo of ImmunoPrecise Antibodies Ltd (IPA)

The financial price action for ImmunoPrecise Antibodies (IPA) demonstrates the business's dependence on pharmaceutical behemoths' investments in primary research, with the indicator standing at 0.05. ImmunoPrecise Antibodies (IPA) develops therapeutic antibodies through alliances with biotech holdings, utilizing AI for molecular analysis. The technology stack is complemented by BioStrand, which implements generative language models for the automated creation of custom medicinal proteins within R&D processes.

Short-Term Debt to Equity Ratio: immunoprecise.com (IPA) for 07/04/2022 - 09/04/2025

Analytical breakdowns for ImmunoPrecise Antibodies

- stock quotes and analyst forecast:
Stock Price ImmunoPrecise Antibodies|IPA - Analyst Consensus Forecast
- market capitalization details:
Market Capitalization ImmunoPrecise Antibodies Ltd|IPA - Company Buyout Price
- book capitalization information:
Net Assets per Single Share ImmunoPrecise Antibodies|IPA - Company Net Assets|Market Value to Book Value Ratio immunoprecise.com|IPA - Cumulative Company Assets
- debt and liquidity details:
Total Debt to Equity Ratio ImmunoPrecise Antibodies|IPA - Long-Term Debt to Capital|Short-Term Debt to Equity ImmunoPrecise Antibodies|IPA - Company Aggregate Debt|Debt to Book Capitalization Ratio ImmunoPrecise Antibodies Ltd|IPA - Long-Term Debt|Company Short-Term Debt ImmunoPrecise Antibodies|Quick Liquidity immunoprecise.com
- company profitability and valuation multiples indicators:
IPA - Final Profit
Summary company analytics:IPA ImmunoPrecise Antibodies Ltd.
Product sample of ImmunoPrecise Antibodies

Institutional capital assesses the investment attractiveness of ImmunoPrecise Antibodies (IPA) through the lens of liquidity, where the change in the ratio of short-term borrowed capital to equity, calculated as the share of liabilities under one year to equity, serves as a detector of credit risks. Amid the scaling of the BioStrand AI platform, this metric confirms the company's ability to fund R&D without a critical debt load, guaranteeing the fundamental stability of the asset.

Competitors of ImmunoPrecise Antibodies (IPA)

Short-Term Debt to Capital TEM|Short-Term Debt to Capital Qiagen Corp (QGEN)|Short-Term Debt to Capital IONS (Ionis Pharmaceuticals)|Short-Term Debt to Capital Coefficient repligen.com (RGEN)|RNA - Short-Term Debt to Equity|CRISPR Therapeutics Inc (CRSP) - Short-Term Debt to Equity Ratio|Sema4 (WGS) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Ultragenyx Corp|Short-Term Debt to Equity Ratio BEAM|Short-Term Debt to Capital sarepta.com|Short-Term Debt to Equity Twist Bioscience, Inc. (TWST)|10x Genomics Inc - Short-Term Debt to Capital Ratio|Short-Term Debt to Equity Intellia NTLA|Stoke Corp (STOK) - Current Liabilities to Capital|BLFS - Short-Term Debt to Equity|Current Liabilities to Equity WVE|Maze Therapeutics (MAZE) - Short-Term Debt to Equity|Sionna Therapeutics, Inc. - Ratio of Short-Term Indebtedness to Capital|PRME (Prime Medicine Corp) - Short-Term Debt to Capital|Current Liabilities to Capital Taysha Corp TSHA|Short-Term Debt to Capital QURE|Short-Term Debt to Equity Ratio meiragtx.com MGTX|Short-Term Debt to Capital RGNX (REGENXBIO)|Short-Term Debt to Capital Coefficient Solid Biosciences Inc (SLDB)|OCGN - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient PacBio Corp PACB|BNTC: Short-Term Debt to Capital|Current Liabilities to Capital designtx.com (DSGN)|Short-Term Debt to Equity Ratio RCKT|FDMT: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital LXEO|Short-Term Debt to Capital korrobio.com (KRRO)|Short-Term Debt to Equity Editas Medicine, Inc. EDIT|SLN: Short-Term Debt to Capital Ratio|PRQR: Short-Term Debt to Equity Ratio|Codexis, Inc. - Short-Term Loans to Capital Ratio|SGMO: Short-Term Debt to Capital|NAUT - Short-Term Debt to Capital Coefficient|MGX (Metagenomi, Inc.) - Short-Term Debt to Capital|Short-Term Debt to Equity DTIL|Short-Term Debt to Equity Generation Bio Co. (GBIO)|BOLD - Current Liabilities to Capital|Short-Term Debt to Capital XCUR (Exicure)|IMNN: Short-Term Debt to Capital Ratio|RXi Pharmaceuticals - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient Mustang Bio, Inc. MBIO|RNAZ: Short-Term Debt to Capital|Current Liabilities to Capital Bionano Genomics (BNGO)|Short-Term Debt to Equity Applied DNA|bluebird bio, Inc (BLUE) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital OMGA|Short-Term Debt to Capital Coefficient singulargenomics.com|Short-Term Debt to Equity Regulus Therapeutics Inc. RGLS|SYRS (Syros Pharmaceuticals Inc.) - Current Liabilities to Equity|Codex DNA - Short-Term Debt to Capital|TCON - Short-Term Debt to Capital|UBX: Short-Term Debt to Capital